Tina Schwabe is currently leading the preclinical biology team at Nine Square Therapeutics. She trained in molecular cell biology and neurobiology as a visiting PhD student at Rockefeller University and as a postdoctoral fellow at Stanford University. Thereafter, she joined Alector as a founding scientist, where she led the studies that discovered novel antibodies elevate the levels of progranulin, a protein depleted in Frontotemporal Dementia. The lead antibodies, which block the clearance of progranulin, are currently being tested in clinical trials. Dr. Schwabe also led discovery and lead optimization of an activating antibody, called AL002, that is currently in clinical trials in people with Alzheimer’s Disease. At Nine Square Therapeutics, Dr. Schwabe’s research focuses on cellular pathways regulating autophagy and lysosomal degradation with the goal of developing novel disease-modifying therapies to address the urgent unmet medical need of neurodegenerative diseases such as Parkinson’s disease.